BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25102106)

  • 1. The use of biologicals in cutaneous allergies - present and future.
    Makris MP; Papadavid E; Zuberbier T
    Curr Opin Allergy Clin Immunol; 2014 Oct; 14(5):409-16. PubMed ID: 25102106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of biologicals in patients with food allergies].
    Agar Muñoz AM; Galván Calle CA
    Rev Alerg Mex; 2023 Dec; 70(4):297-299. PubMed ID: 38506875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics for atopic diseases: Indication, side effect management, and new developments.
    Jappe U; Beckert H; Bergmann KC; Gülsen A; Klimek L; Philipp S; Pickert J; Rauber-Ellinghaus MM; Renz H; Taube C; Treudler R; Wagenmann M; Werfel T; Worm M; Zuberbier T
    Allergol Select; 2021; 5():1-25. PubMed ID: 33426426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fascinating story of the discovery & development of biologicals for use in clinical medicine.
    Malaviya AN; Mehra NK
    Indian J Med Res; 2018 Sep; 148(3):263-278. PubMed ID: 30425216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologicals.
    de Carvalho JF; Appenzeller S; Shoenfeld Y
    Int J Rheumatol; 2012; 2012():892873. PubMed ID: 22536258
    [No Abstract]   [Full Text] [Related]  

  • 6. Fifty years of advancing biologicals and beyond.
    Gupta R; Elwyn G; Vyas G; Thorpe R; Baylor N
    Biologicals; 2024 Feb; 85():101727. PubMed ID: 37992427
    [No Abstract]   [Full Text] [Related]  

  • 7. An overview of the effects of anti-IgE therapies.
    Yalcin AD
    Med Sci Monit; 2014 Sep; 20():1691-9. PubMed ID: 25241913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
    Andreae DA; Wang J
    Pediatrics; 2014 Nov; 134 Suppl 3():S160. PubMed ID: 25363953
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Bel EH; Ortega HG; Pavord ID
    N Engl J Med; 2014 Dec; 371(25):2434. PubMed ID: 25517711
    [No Abstract]   [Full Text] [Related]  

  • 10. Mepolizumab treatment in patients with severe eosinophilic asthma.
    Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
    N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to watch in 2015.
    Reichert JM
    MAbs; 2015; 7(1):1-8. PubMed ID: 25484055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab: a review of its use in patients with chronic spontaneous urticaria.
    McCormack PL
    Drugs; 2014 Sep; 74(14):1693-9. PubMed ID: 25217402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of atopic dermatitis.
    Peng W; Novak N
    Clin Exp Allergy; 2015 Mar; 45(3):566-74. PubMed ID: 25610977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Auto-anti-IgE": naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation.
    Chan YC; Ramadani F; Santos AF; Pillai P; Ohm-Laursen L; Harper CE; Fang C; Dodev TS; Wu SY; Ying S; Corrigan CJ; Gould HJ
    J Allergy Clin Immunol; 2014 Dec; 134(6):1394-1401.e4. PubMed ID: 25112697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of biologics in intractable urticaria.
    Cooke A; Bulkhi A; Casale TB
    Biologics; 2015; 9():25-33. PubMed ID: 25926715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological drugs in ANCA-associated vasculitis.
    Lutalo PM; D'Cruz DP
    Int Immunopharmacol; 2015 Aug; 27(2):209-12. PubMed ID: 25907243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Iikura M; Hojo M; Sugiyama H
    N Engl J Med; 2014 Dec; 371(25):2433-4. PubMed ID: 25517713
    [No Abstract]   [Full Text] [Related]  

  • 20. Churg-Strauss syndrome.
    Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
    Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.